Skip to main content

precision medicine

Trending From ACCC
12/19/2023
Rania Emara explains the social barriers that socioeconomically affected rural groups experience with precision medicine and provides some insight into possible solutions.
Rania Emara explains the social barriers that socioeconomically affected rural groups experience with precision medicine and provides some insight into possible solutions.
Rania Emara explains the social...
12/19/2023
Journal of Clinical Pathways
News
06/03/2020
HRD test results used in published and ongoing clinical trials for PARP inhibitor-treatment of ovarian cancer are not equivalent, according to the results of a study presented at the American Society of Clinical...
HRD test results used in published and ongoing clinical trials for PARP inhibitor-treatment of ovarian cancer are not equivalent, according to the results of a study presented at the American Society of Clinical...
HRD...
06/03/2020
Journal of Clinical Pathways
Prior Authorization for Comprehensive Genomic Profiling in Clinical Pathways
Interview
05/27/2020
At the Community Oncology Alliance (COA) Annual Meeting (April 24, 2020), Lee Schwartzberg, MD, FACP, West Cancer Center and Research Institute (a member of OneOncology), moderated a stakeholder panel discussion on...
At the Community Oncology Alliance (COA) Annual Meeting (April 24, 2020), Lee Schwartzberg, MD, FACP, West Cancer Center and Research Institute (a member of OneOncology), moderated a stakeholder panel discussion on...
At the...
05/27/2020
Journal of Clinical Pathways
Payer Perceptions of Genomic Precision Medicine
Healthcare Economist
05/20/2020
Jason Shafrin, PhD, highlights a study that shows which factors payers consider when evaluating whether to provide coverage for genetic tests as well as how they value these factors.
Jason Shafrin, PhD, highlights a study that shows which factors payers consider when evaluating whether to provide coverage for genetic tests as well as how they value these factors.
Jason Shafrin, PhD, highlights a...
05/20/2020
Journal of Clinical Pathways
Research in Review
06/07/2017
JCP Editors
A panel of breast cancer experts offered an education session on the value of standard and genomic testing for breast cancer at the 2017 American Society of Clinical Oncology Annual Meeting (June 2-6, 2017; Chicago,...
A panel of breast cancer experts offered an education session on the value of standard and genomic testing for breast cancer at the 2017 American Society of Clinical Oncology Annual Meeting (June 2-6, 2017; Chicago,...
A...
06/07/2017
Journal of Clinical Pathways
Research in Review
06/01/2017
JCP Editors
Next-generation sequencing (NGS) may be economically beneficial for select patients with treated in the community oncology setting, but it should be carefully applied due to potential associated financial burdens,...
Next-generation sequencing (NGS) may be economically beneficial for select patients with treated in the community oncology setting, but it should be carefully applied due to potential associated financial burdens,...
...
06/01/2017
Journal of Clinical Pathways
Research in Review
06/01/2017
JCP Editors
Transcriptome sequencing that identifies pathogens in prostate cancer biopsies can be used as a signature for disease detection, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017;...
Transcriptome sequencing that identifies pathogens in prostate cancer biopsies can be used as a signature for disease detection, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017;...
...
06/01/2017
Journal of Clinical Pathways
Research in Review
05/31/2017
JCP Editors
A new comprehensive next generation sequencing (NGS) platform is more likely than targeted NGS platforms to identify clinically relevant and actionable molecular alterations in metastatic cancers, according to...
A new comprehensive next generation sequencing (NGS) platform is more likely than targeted NGS platforms to identify clinically relevant and actionable molecular alterations in metastatic cancers, according to...
A new...
05/31/2017
Journal of Clinical Pathways
Research in Review
04/07/2017
JCP Editors
High-throughput genomic analyses may improve outcomes in patients with types of metastatic cancer, according to results of a recent trial published in Cancer Discovery (published online April 1, 2017;...
High-throughput genomic analyses may improve outcomes in patients with types of metastatic cancer, according to results of a recent trial published in Cancer Discovery (published online April 1, 2017;...
...
04/07/2017
Journal of Clinical Pathways
Research in Review
04/06/2017
JCP Editors
Patients with a specific type of metastatic colorectal cancer who are chemotherapy-resistant benefit from treatment with a gene-targeting regimen. ----- Related Content ESMO announces changes to metastatic...
Patients with a specific type of metastatic colorectal cancer who are chemotherapy-resistant benefit from treatment with a gene-targeting regimen. ----- Related Content ESMO announces changes to metastatic...
...
04/06/2017
Journal of Clinical Pathways